



Vaccinex to present its ActivMAb® Antibody Discovery Technology at the 2015 PEGS Europe Summit

October 27, 2015

ROCHESTER, N.Y., Oct. 27, 2015 — Vaccinex Inc. announced today that it will present information on its proprietary, mammalian cell-based antibody selection platform on Monday, November 2nd at the PEGS Europe summit held in Lisbon, Portugal. Vaccinex's antibody discovery platform, ActivMAb®, uses a vaccinia virus-based library technology that enables efficient selection of fully functional IgG antibodies from highly diverse, human immunoglobulin gene libraries expressed on both viral particles and the membrane of the mammalian cells they infect. This novel approach combines the advantages of virus panning and cell sorting into one technology, and rivals other commercial platforms in terms of throughput and diversity examined. Furthermore, compared to other selection technologies, it has the advantage of being a true mammalian cell-based platform that has built in selection for antibodies with favorable development properties.

About Vaccinex, Inc.

Vaccinex, Inc. is a privately held clinical-stage immunotherapy company engaged in the discovery and development of human therapeutic monoclonal antibodies to treat cancer and neurodegenerative diseases. The Company has completed phase 1 clinical trials in solid tumors and multiple sclerosis and is currently engaged in a phase 2 clinical trial in Huntington's disease. Vaccinex utilizes its proprietary ActivMAb® Antibody Discovery Technology for rapid, mammalian cell-based antibody selection to build its antibody pipeline and in service to its biopharmaceutical partners. ActivMAb® combines the advantages of rapid and sensitive selection by virus panning and cell sorting in one technology, with intrinsic selection of antibodies that are efficiently expressed in mammalian cells and have desirable solubility and stability properties. Vaccinex is based in Rochester, New York. For more information and to contact Vaccinex, visit www.vaccinex.com.

CONTACT: Vaccinex info@vaccinex.com

Cautionary Note on Forward-Looking Statements

This press release contains forward-looking statements reflecting the current beliefs and expectations of management. Words such as "may," "believe," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions, as well as other words or expressions referencing future events, conditions or circumstances, are intended to identify forward-looking statements. Forward-looking statements contained in this press release include statements about the initiation of a Phase 2 clinical trial for the Company's lead monoclonal antibody, VX15/2503. Forward-looking statements in this press release involve substantial risks and uncertainties that could cause our performance or achievements to differ significantly from those expressed or implied by the forward-looking statements, including as a result of the inherent challenges in clinical development. All forward-looking statements are based on Vaccinex's expectations and assumptions as of the date of this press release, and actual results may differ materially. Except as required by law, Vaccinex expressly disclaims any responsibility to update any forward-looking statement contained herein, whether as a result of new information, future events or otherwise.